Background: Isocitrate dehydrogenase (IDH) catalyzes the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Mutations of Arg-172 in IDH2 to Cys, His, Leu or Ser abolish magnesium binding and the conversion of isocitrate to alpha-ketoglutarate. Instead, alpha-ketoglutarate is converted to R-2-hydroxyglutarate. Elevated levels of R-2-hydroxyglutarate are correlated with an elevated risk of malignant brain tumors.
Immunogen: A synthetic peptide from the internal region of human IDH2 which includes the mutation of R172H.
Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 50% glycerol
Species Reactivity: Anti-IDH2(R172H) antibody recognizes IDH2(R172H) of vertebrates.
Storage Conditions: Store at -20°C. Avoid freeze / thaw cycles.
Western blot:
Western blot analysis of recombinant IDH2(R172H) and wild-type IDH2 proteins. Purified his-tagged IDH2(R172H) protein (Cat. # 10201) and wild-type IDH2 protein (Cat. # 10200) were blotted with anti-IDH2(R172H) monoclonal antibody (Cat. # 26084) (left panel). Proteins loading were blotted with anti-IDH2 monoclonal antibody (right panel).
Immunofluorescence:
Immunofluorescence of cells expressing IDH2 proteins with anti-IDH2 (R172H) antibody. HEK293T cells were transfected with pCDNA3-GFP-IDH2 (WT) plasmid (left column) or pCDNA3-GFP-IDH2 (R172H) plasmid (right column), then fixed and stained with anti-IDH2 (R172H) monoclonal antibody (Cat. #26084).